FDA Advisory Committee to Review Lykos Therapeutics’ MDMA-Assisted Therapy in Early June

Save the date: the FDA will hold an advisory committee meeting to review Lykos Therapeutics’ New Drug Application (NDA) for MDMA-assisted psychotherapy in the treatment of PTSD on June 4th, 2024. The purpose of FDA advisory committees is to provide “independent, expert advice” to the agency [1]. In this case, it will be the agency’s Psychopharmacologic Drugs Advisory Committee (PDAC) that is…

Source